Phibro Animal Health Corporation has acquired the medicated feed additive product portfolio and certain water-soluble products from Zoetis Inc.
The acquisition includes several feed additives widely used in the poultry industry, including Avatec (lasalocid), BMD (bacitracin) and Zoamix (zoalene).
The company said this acquisition marks a significant step in furthering Phibro’s purpose to optimize global animal health and nutrition for better lives and a more sustainable world.
“Adding this new lineup of medicated feed additives and water-soluble products across cattle, swine and poultry will complement and expand Phibro’s species and product portfolios, helping customers meet the highest standards of animal care, prevent disease, and enhance nutrition around the world,” said Jack C. Bendheim, Chairman, president and CEO of Phibro.
The acquisition includes more than 37 product lines sold across approximately 80 countries, six manufacturing sites in the US, Italy and China, and a team of more than 300 employees who primarily support the manufacturing and distribution activities of the business.
“This is a win-win-win,” noted Larry Miller, Phibro’s chief operating officer.
“For our customers, it broadens the solution options and expertise that Phibro brings to support animal health globally; for consumers, it helps continue to ensure that food is produced safely and sustainably; and for our investors, it expands and diversifies our revenue base, ultimately generating funding to support future investment in additional fast-growing animal health product categories.”
